Analyst Expectations for Arcutis Biotherapeutics's Future
Portfolio Pulse from Benzinga Insights
In the last 3 months, 11 analysts have offered 12-month price targets for Arcutis Biotherapeutics (NASDAQ:ARQT), with an average price target of $41.55, down 15.2% from the previous average of $49.00.
June 12, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcutis Biotherapeutics (ARQT) has an average 12-month price target of $41.55, down 15.2% from the previous average of $49.00, based on 11 analyst ratings.
The average 12-month price target for ARQT has decreased by 15.2% from the previous average, indicating a potential change in analyst sentiment. However, the overall analyst ratings remain bullish, with 9 bullish and 2 somewhat bullish ratings in the last quarter. This suggests that the stock may experience short-term fluctuations, but the overall outlook remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100